TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: 100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: 100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
Study: NCT04373226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude comparison tasks and neuropsychological testing
Description: neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Magnitude comparison tasks and neuropsychological testing
Description: neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
Study: NCT02324283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Study: NCT01340586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, Once, 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, Twice, 15 days
Study: NCT03053947

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Ketamine
Description: Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
Study: NCT01172626

Intervention type: DRUG
Intervention: valproate sodium
Description: oral administration,15-30mg/kg,daily

Intervention type: GENETIC
Intervention: Polymorphism Analysis
Description: Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
Study: NCT03385148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Sgc8
Description: underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
Study: NCT02432586

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Education
Description: Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
Study: NCT03824002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart insulin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart insulin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
Study: NCT02588235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe and Atorvastatin
Description: atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin (20 mg/day）
Study: NCT05089643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
Study: NCT01051687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit.
Study: NCT01980095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-105
Description: The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
Study: NCT03685630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection
Study: NCT03502525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Break the Cycle Intervention
Description: The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
Study: NCT02046707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: initial evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Period of cardiac rehabilitation
Study: NCT00755248

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting
Description: Coronary Artery Bypass Grafting on- or off-pump
Study: NCT02046707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: final evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Concentric and eccentric exercise sessions
Study: NCT02092285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 50mg or 100mg solution for injection; subcutaneous injection
Study: NCT04127695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-0805
Description: ABBV-0805 administered by IV infusion.
Study: NCT02225093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Oral /.L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Placebo to Match (PTM)
Description: Oral
Study: NCT00774293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica and Bryonia
Description: Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
Study: NCT02114138

Intervention type: PROCEDURE
Intervention: pathogenesis of perioperative acute kidney injury
Description: understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: urine collection
Description: urine collection will be performed on both the control group and hospitalized participants

Intervention type: DIAGNOSTIC_TEST
Intervention: urine collection
Description: urine collection will be performed on both the control group and hospitalized participants
Study: NCT01699230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
Study: NCT04451941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: RecoveriX with individual EEG calibration
Description: RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RecoveriX without individual EEG calibration
Description: RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
Study: NCT01574508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transient Continuous Subcutaneous Insulin Infusion
Description: Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transient Multiple Daily Insulin Injections
Description: Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
Study: NCT01908530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprobe glucose sensor
Description: Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprobe glucose sensor
Description: Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprobe glucose sensor
Description: Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
Study: NCT01372969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cx601
Description: Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
Study: NCT01023711

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated H1N1 vaccine
Description: 0.5 ml IM into Deltoid region of arm

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated H1N1 vaccine
Description: 0.5 mL IM X 1 dose
Study: NCT01941329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of ranibizumab
Study: NCT01717872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
Study: NCT03373929

Intervention type: DEVICE
Group type: OTHER
Intervention: PFO Closure Rate
Description: Suture Mediated PFO Closure and Septal Repair

Intervention type: DEVICE
Group type: OTHER
Intervention: PFO Closure Rate
Description: Suture Mediated PFO Closure and Septal Repair

Intervention type: DEVICE
Group type: OTHER
Intervention: Published PFO Device Closure
Description: Suture Mediated PFO Closure and Septal Repair

Intervention type: DEVICE
Group type: OTHER
Intervention: Published PFO Device Closure
Description: Suture Mediated PFO Closure and Septal Repair
Study: NCT03560310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg twice daily and ASA 75-100 mg daily
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 75-160 mg daily
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
Study: NCT03400852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-1411
Description: MNK-1411 (1 mg/mL suspension) for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-1411
Description: MNK-1411 (1 mg/mL suspension) for subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo suspension for subcutaneous injection
Study: NCT05134558

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Xenon-enhanced Ventilation CT-guided Radiotherapy
Description: Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
Study: NCT04127695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-0805
Description: ABBV-0805 administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-0805
Description: ABBV-0805 administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-0805
Description: ABBV-0805 administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ABBV-0805
Description: Placebo ABBV-0805 administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ABBV-0805
Description: Placebo ABBV-0805 administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ABBV-0805
Description: Placebo ABBV-0805 administered by IV infusion.
Study: NCT04001348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Max Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Pediatric
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo 29 Gauge
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo 23 Gauge
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study: NCT00896298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin
Description: Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT00494585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701
Description: 80 mg orally twice a day for 30 days
Study: NCT01359345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadollinum
Description: use of on injection gadollinum Iv for imaging
Study: NCT02248805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD007
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD007
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD007
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD007
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
Study: NCT01578681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Expiration Open glottis inferolateral (ELTGOL)
Description: Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Patient will be instructed to do muscle stretching of the thorax
Study: NCT04402424

Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal Immunochemical Testing
Description: Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
Study: NCT00545090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months
Study: NCT01067274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesanoid (ATRA)
Description: 45 mg/m2/day in two divided doses from D8 to D28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesanoid (ATRA)
Description: 45 mg/m2/day in two divided doses from D8 to D28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesanoid (ATRA)
Description: 45 mg/m2/day in two divided doses from D8 to D28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACITIDINE (VIDAZA)
Description: 75 mg/m2/12h SC from D1 to D5
Study: NCT02313246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy
Description: This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.